Peer Support Intervention for Suicide Prevention Among High-Risk Adults in Michigan: A Randomized Clinical Trial
Recommended Citation
Pfeiffer PN, Abraham KM, Lapidos A, Vega E, Jagusch J, Garlick J, Pasiak S, Ganoczy D, Kim HM, Ahmedani B, Ilgen M, and King C. Peer Support Intervention for Suicide Prevention Among High-Risk Adults in Michigan: A Randomized Clinical Trial. JAMA Netw Open 2025; 8(5):e2510808.
Document Type
Article
Publication Date
5-1-2025
Publication Title
JAMA Netw Open
Abstract
IMPORTANCE: Innovative approaches to address interpersonal risk factors for suicide attempts and suicidal ideation may help reduce persistently elevated suicide rates in the US.
OBJECTIVE: To determine whether Peers for Valued Living (PREVAIL), a posthospital peer support intervention, reduces suicide attempts and suicidal ideation among adults psychiatrically hospitalized for suicide risk.
DESIGN, SETTING, AND PARTICIPANTS: This single-masked, randomized clinical trial recruited adult psychiatric inpatients aged 18 years or older from 3 Michigan-based facilities between June 22, 2018, and December 30, 2022. The study compared 3 months of the PREVAIL intervention plus enhanced usual care with enhanced usual care only, with 3 months of postintervention follow-up.
INTERVENTION: One-on-one support from a peer specialist initiated during hospital admission and continued 3 months after discharge.
MAIN OUTCOMES AND MEASURES: Suicide attempts were measured using the Columbia Suicide Severity Rating Scale, and suicidal ideation was measured using the Beck Scale for Suicidal Ideation at 3 and 6 months after randomization.
RESULTS: Of 5310 patients screened, 455 were randomized using a minimization algorithm. A total of 229 participants were randomized to the PREVAIL peer mentorship arm (mean [SD] age, 32.4 [14.0] years, 134 women [58.5%]), and 226 were randomized to the enhanced usual care arm (mean [SD] age, 31.6 [13.5] years; 139 women [61.5%]). In the intention-to-treat sample with nonmissing data, the percentage of participants with any suicide attempt over 6 months (including participants who only completed 3-month follow-up assessments) was 17.2% (28 of 163) for enhanced usual care and 14.9% (24 of 161 with 2 deaths by suicide) for PREVAIL. Mean (SD) suicidal ideation scores were 4.3 (95% CI, 3.2-5.3) for enhanced usual care and 4.9 (95% CI, 3.7-6.1) for PREVAIL at 6 months. There were no statistically significant effects of the intervention for either outcome in the primary analyses. In post hoc analyses, the interaction between study arm and the COVID-19 pandemic was statistically significant. The enhanced usual care arm had a mean (SD) 6-month suicidal ideation score of 3.5 (6.1) before and 6.1 (7.4) after the pandemic vs the PREVAIL arm (mean [SD] scores, 5.0 [7.7] and 4.5 [6.6], respectively). There were 2 study-related adverse events, with 1 resulting in participant withdrawal from the intervention arm.
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the peer-delivered PREVAIL intervention up to 3 months after discharge did not significantly differ from enhanced usual care in terms of reducing subsequent suicide attempts or suicidal ideation.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03373916.
Medical Subject Headings
Adult; Female; Humans; Male; Middle Aged; Michigan; Peer Group; Risk Factors; Single-Blind Method; Social Support; Suicidal Ideation; Suicide Prevention; Suicide, Attempted; Young Adult
PubMed ID
40434775
Volume
8
Issue
5
First Page
2510808
Last Page
2510808
